This Article Full Text (PDF) All Versions of this Article: 1078155208097632v1 15/2/119    most recent References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Dasanu, C. A Articles by Alexandrescu, D. T PubMed PubMed Citation Articles by Dasanu, C. A Articles by Alexandrescu, D. T Social Bookmarking                         What's this?

Acute retinal pigment epithelial detachment secondary to pamidronate administration

Practicing Medical Oncologist, Seattle, WA, USA, c_dasanu{at}yahoo.com

Doru T Alexandrescu, MD

Georgetown University, Washington, DC, USA

Bisphosphonates are associated with an important number of inflammatory ocular side-effects including but not limited to conjunctivitis, episcleritis, scleritis, uveitis, and optic neuritis. The intravenous bisphosphonates appear to be linked with more severe ocular inflammation than the orally administered ones. These eye complications tend to resolve with the bisphosphonate discontinuation and can re-occur with its re-challenge. We present here the first case of an acute retinal pigment epithelial detachment associated with pamidronate infusion in a 59-year-old patient with metastatic prostate cancer. J Oncol Pharm Practice (2009) 15: 119—121.

Key Words: intravenous bisphosphonate • pamidronate • ocular inflammation • macular degeneration • retinal pigment epithelial detachment

This version was published on June 1, 2009

Journal of Oncology Pharmacy Practice, Vol. 15, No. 2, 119-121 (2009)
DOI: 10.1177/1078155208097632


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?